All In Biotech

Drug Trial Radar · NCT03137173

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

A Randomized, Double-blind, Multicenter Study to Establish the Safety and Efficacy of Ceftobiprole Medocaril Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 679 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

679

Actual

Start

Feb 19, 2018

Primary completion

Apr 22, 2019

Study completion Apr 22, 2019

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
May 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).

Conditions

  • Acute Bacterial Skin and Skin Structure Infections

Interventions

  • ceftobiprole medocarilDrug

    ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.

  • vancomycin+aztreonamDrug

    Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor. Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Clinical ResponseTime frame: 48-72 hours after start of study drug treatment

Locations

34 sites in 4 countries. Site status is shown where the registry gives one.

  • Physician Alliance Research Center

    Anaheim, California

  • Saint Joseph's Clinical Research

    Anaheim, California

  • eStudySite - Chula Vista - PPDS

    Chula Vista, California

  • Central Valley Research LLC

    Fresno, California

  • Marvel Clinical Research

    Huntington Beach, California

  • eStudySite - La Mesa - PPDS

    La Mesa, California

  • Omnibus Clinical Research

    La Palma, California

  • Alliance Research LLC

    Long Beach, California

  • Long Beach Clinical Trials

    Long Beach, California

  • Central Valley Research, LLC

    Modesto, California

  • Gonzalez MD and Aswad MD Health Services

    Coral Gables, Florida

  • L&C Professional Medical Research Institute

    Miami, Florida

  • Mercury Street Medical Group

    Butte, Montana

  • eStudySite - Las Vegas - PPDS

    Las Vegas, Nevada

  • Excel Clinical Research

    Las Vegas, Nevada

  • South Jersey Infectious Disease

    Somers Point, New Jersey

  • University Multiprofile Hospital for Active Treatment

    Pleven, Bulgaria

  • University Multiprofile Hospital for Active Treatment

    Plovdiv, Bulgaria

  • University Multiprofile Hospital for Active Treatment

    Rousse, Bulgaria

  • "University Multiprofile Hospital for Active Treatment and Emergency Medicine ""N. I. Pirogov"", Clinic of Purulent-Septic Surgery-"N.I. Pirogov""

    Sofia, Bulgaria

  • Kaposi Mor Teaching Hospital

    Kaposvár, Hungary

  • CRU Hungary Ltd.

    Miskolc, Hungary

  • University of SzegednAlbert Szent-Gyorgyi Clinical Center

    Szeged, Hungary

  • Csolnoky Ferenc Hospital

    Veszprém, Hungary

  • Dnipropetrovsk I.I. Mechnуkov Regional Clinical Hospital, Surgery Department #2

    Dnipro, Ukraine

  • Ivano-Frankivsk City Clinical Hospital Surgery 1

    Ivano-Frankivsk, Ukraine

  • Ivano-Frankivsk City Clinical Hospital General Surgery

    Ivano-Frankivsk, Ukraine

  • Kyiv City Clinical Hospital

    Kyiv, Ukraine

  • Public City Clinical Hospital of Emergency Medical Care

    Lviv, Ukraine

  • Lviv Regional Clinical Hospital

    Lviv, Ukraine

  • Central City Clinical Hospital

    Uzhhorod, Ukraine

  • Vinnytsia M.I. Pyrohov Regional Clinical Hospital

    Vinnytsia, Ukraine

  • Zaporizhia City Clinical Hospital of Urgent and Emergency Medical Care

    Zaporizhia, Ukraine

  • Central District Hospital

    Zhytomyr, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.